NA
MACK

NewEdge Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

NewEdge Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,406
Closed -$20.8K – 4069
2024
Q1 		$20.8K Hold
1,406
– – ﹤0.01% 2616
2023
Q4 		$18.9K Hold
1,406
– – ﹤0.01% 2586
2023
Q3 		$17.3K Hold
1,406
– – ﹤0.01% 2415
2023
Q2 		$17.3K Hold
1,406
– – ﹤0.01% 2422
2023
Q1 		$17.3K Hold
1,406
– – ﹤0.01% 2387
2022
Q4 		$16 Buy
+1,406
New +$11.6K ﹤0.01% 3638
2017
Q3 		– Sell
-1,787
Closed -$20.1K – 1349
2017
Q2 		$20.1K Buy
+1,787
New +$36.5K ﹤0.01% 738

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NewEdge Advisors's MACK Position: Q2 2024 in Review

NewEdge Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 1,406 shares — an estimated $20.8K sold.

NewEdge Advisors first reported a position in MACK in Q2 2017 and held it in 7 quarters. The position peaked at $20.8K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • NewEdge Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • NewEdge Advisors sold 1,406 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $20.8K.
  • NewEdge Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 7 quarters.
  • NewEdge Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $20.8K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.